Multi-center Study on New Cardiovascular Remodeling and Function Parameters in Hypertension
Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Nov 27, 2022
Trial Information
Current as of January 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different types of high blood pressure, known as hypertension, affect the heart and blood vessels over time. Researchers want to understand the connection between hypertension and serious heart-related events by measuring various heart and blood vessel functions. They plan to enroll 2,200 participants aged 30 to 75 from 20 different research centers. Participants will be asked to come in for check-ups at 12, 24, 36, and 48 months after joining the study, where they will undergo physical exams, heart tests (like ECG and echocardiography), and blood tests.
To be eligible for the study, participants should be between 30 and 75 years old and have high blood pressure readings, either by not using blood pressure medications or having a history of hypertension. They also need to have a normal heart function. However, people with certain severe heart or kidney conditions, or those who are pregnant or breastfeeding, cannot participate. If you decide to join, you'll be contributing to important research that could help improve care for people with hypertension. Your participation will involve regular check-ups and tests to monitor your heart health over time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 30-75 years old;
- • 2. No antihypertensive drugs were used and three blood pressure measurements were conducted on different days, with systolic blood pressure ≥ 140 mmHg (1 mmHg=0.133 kPa) and/or diastolic blood pressure ≥ 90 mmHg; or have a history of hypertension and are using antihypertensive drugs, even if the blood pressure is lower than 140/90 mmHg;
- • 3. Left ventricular ejection fraction was normal (LVEF ≥ 0.5).
- • 4. All patients agreed to participate in the experiment and signed the informed consent form.
- Exclusion Criteria:
- • 1. Secondary hypertension caused by renal parenchymal diseases, renal vascular diseases, coarctation of aorta and endocrine system diseases;
- • 2. Severe cardiovascular and cerebrovascular diseases; heart valve disease; persistent atrial fibrillation and severe arrhythmia; previously undergone cardiovascular disease surgery;
- • 3. Abnormal liver function; abnormal renal function and diabetes;
- • 4. Pregnant or breastfeeding women;
- • 5. Expected survival time due to non-cardiovascular disease\<4 years;
- • 6. Patients with poor echocardiographic image quality.
Trial Officials
Mei Zhang, PhD
Principal Investigator
Qilu Hospital of Shandong University
About Qilu Hospital Of Shandong University
Qilu Hospital of Shandong University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Affiliated with Shandong University, the hospital integrates clinical practice with education and research, fostering an environment that promotes scientific discovery and the development of new therapies. With a commitment to high standards of clinical excellence and ethical research practices, Qilu Hospital plays a pivotal role in enhancing patient outcomes and contributing to the global medical community through a diverse range of clinical trials and studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials